trending Market Intelligence /marketintelligence/en/news-insights/trending/pu3yquhz_fxcdubrbzkdbw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA records violations at Alkem's manufacturing plants in India, US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA records violations at Alkem's manufacturing plants in India, US

Alkem Laboratories Ltd. said the U.S. Food and Drug Administration recorded 13 violations at its manufacturing facilities in India and the U.S.

The regulator issued a Form 483 following an inspection at the company's plants in Daman, India, and St. Louis.

A Form 483 is issued when investigators observe any conditions or practices that may have violated the Food Drug and Cosmetic Act and could later pose health hazards to consumers.

The company has already submitted a corrective and preventive action plan to the FDA for its U.S.-based facility.

Alkem plans to submit a response for the Indian facility in the future.